drugset / Trial / NCT04976595

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

NCT04976595

Phase 4 Unknown 218 enrolled Acerus Pharmaceuticals Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.

Timeline

Start
2021-07-01
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 11 mg Intranasal

Indications